Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice

American Journal Geriatric Pharmacotherapy

Volumn 5, Issue 3, 2007, Pages 185-194

  Harley, Carolyn R ^a   Gandhi, Sanjay ^b   Blasetto, James ^b   Heien, Herbert ^c   Sasane, Rahul ^b   Nelson, Stephanie P ^c  

^a Health Economics and Outcomes   (United States)

^b ASTRAZENECA   (United Kingdom)

^c Health Economics and Outcomes Research   (United States)

Author keywords

3 hydroxy 3 methylglutaryl cocnzyme A inhibitors; dyslipidemia; elderly; goal; lipids; low density lipoprotein cholesterol; Medicare; statins

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; COVARIANCE; DOSE RESPONSE; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; GERIATRIC PATIENT; GOAL ATTAINMENT; HEALTH CARE PLANNING; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICARE; PATIENT COMPLIANCE; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL MODEL; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; COHORT STUDIES; CORONARY DISEASE; DATABASES, FACTUAL; FATTY ACIDS, MONOUNSATURATED; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INDOLES; LOVASTATIN; MALE; MANAGED CARE PROGRAMS; ODDS RATIO; PRAVASTATIN; PYRIMIDINES; PYRROLES; RETROSPECTIVE STUDIES; SIMVASTATIN; SULFONAMIDES; TREATMENT OUTCOME;

EID: 35848948801     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2007.10.002     Document Type: Article

References (32)

1. US Census Bureau. US interim projections by age, sex, race, and Hispanic origin. Available at: (September 13, 2007). http://www.census.gov/ipc/www/usinterimproj Accessed
2. American Heart Association. Heart Disease and Stroke Statistics-2006 Update (2006-September 13, 2007), American Heart Association, Dallas, Tex. http://www.circ.ahajournals.org/cgi/reprint/circulationaha.105.171600vl. pdf Accessed
3. Miettinen T., Pyorala K., Olsson A., et al. Cholesterol- lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: Findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 96 (1997) 4211-4218
4. Lewis S., Moye L., Sacks F., et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 129 (1998) 681-689
5. Hunt D., Young P., Simes J., et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Ann Intern Med 134 (2001) 931-940
6. Shepherd J., Blauw G., Murphy M., et al., PROSPER Study Group (PROspective Study of Pravastatin in the Elderly at Risk). Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 360 (2002) 1623-1630
7. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 344 (1994) 1383-1389
8. Sacks F., Pfeffer M., Moye L., et al., Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
9. Nissen S., Nicholls S., Sipahi I., et al., ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 295 (2006) 1556-1565
10. Waters D., LaRosa J., Barter P., et al. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J Am Coll Cardiol 48 (2006) 1793-1799
11. The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
12. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet. 360 (2002) 7-22
13. Grundy S., Cleeman J., Merz C., et al., National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. [published correction appears in Circulation. 2004;110:763]. Circulation 110 (2004) 227-239
14. Crestor. [package insert]. Wilmington, Del: AstraZeneca Pharmaceuticals LP (2003). http://www.astrazeneca-us.com/pi/crestor.pdf Available at: Accessed September 13,2007
15. Lipitor. [package insert]. New York, NY: Pfizer Inc (2004). http://www.lipitor.com/content/lipitor_pii.pdf Available at: Accessed September 13, 2007
16. Pravachol. [package insert]. Princeton, NJ: Bristol-Myers Squibb Co (2004). http://www.bms.com/cgi-bin/anybin.pl?sql=pi_seq=56 Available at: Accessed September 13, 2007
17. Mevacor. [package insert]. Whitehouse Station, NJ: Merck & Co, Inc (2004). http://www.merckfrosst.ca/assets/en/pdf/products/mevacor_1080-a_2_07-E.p df Available at: Accessed September 13, 2007
18. Zocor. [package insert]. Whitehouse Station, NJ: Merck & Co, Inc (2004). http://www.merck.com/product/usa/pi_circulars/z/zocor/zocor_brief.pdf Available at: Accessed September 13, 2007
19. Lescol. [package insert]. East Hanover, NJ: Novartis Pharmaceuticals (2003). http://www.novartis.ca/downloads/en/products/lescol_scrip_e.pdf Available at: Accessed September 13, 2007
20. Paoletti R., Fahmy M., Mahla G., et al. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: A randomized, double-blind study. J Cardiovasc Risk 8 (2001) 383-390
21. Olsson A., Istad H., Luurila O., et al., Rosuvastatin Investigators Group. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 144 (2002) 1044-1051
22. McKenney J., Jones P., Adamczyk M., et al., STELLAR Study Group. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: Results from the STELLAR trial. Curr Med Res Opin 19 (2003) 689-698
23. * Trial). Am J Cardiol 92 (2003) 152-160
24. Crouse III J., Raichlen J., Riley W., et al., METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: The METEOR Trial. JAMA 297 (2007) 1344-1353
25. Stender S., Schuster H., Barter P., et al., MERCURY I Study Group. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial [published correction appears in Diabetes Obes Metab. 2005;7:460]. Diabetes Obes Metab 7 (2005) 430-438
26. Bullano M., Wertz D., Yang G., et al. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Pharmacotherapy 26 (2006) 469-478
27. Meyer J., Schultz J., O'Donnell J., et al. Patterns and effectiveness of lipid-lowering therapies in a managed care environment. Value Health 8 (2005) 601-612
28. Schultz J., O'Donnell J., McDonough K., et al. Determinants of compliance with statin therapy and low- density lipoprotein cholesterol goal attainment in a managed care population. Am J Manag Care 11 (2005) 306-312
29. Parris E., Lawrence D., Mohn L., and Long L. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care 28 (2005) 595-599
30. Wei L., Wang J., Thompson P., et al. Adherence to statin treatment and readmission of patients after myocardial infarction: A six year follow up study. Heart 88 (2002) 229-233
31. Benner J., Glynn R., Mogun H., et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 288 (2002) 455-461
32. Frolkis J., Pearce G., Nambi V., et al. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med 113 (2002) 625-629